SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ottevanger P. B.)
 

Sökning: WFRF:(Ottevanger P. B.) > (2020) > Final results from ...

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

Ray-Coquard, I. (författare)
GINECO and Medical Oncology Department, Centre Léon Bérard, University Claude Bernard Lyon, Lyon, France
Cibula, D. (författare)
AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty Hospital, Charles University of Prague, Prague, Czech Republic
Mirza, M.R. (författare)
NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
visa fler...
Reuss, A. (författare)
AGO and Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany
Ricci, C. (författare)
MITO and Division of Gynecologic Oncology, Department of Women and Childrens Health and Public Health, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
Colombo, N. (författare)
MaNGO and European Institute of Oncology and University of Milan Bicocca, Milan, Italy
Koch, H. (författare)
AGO Austria and Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria
Goffin, F. (författare)
BGOG and CHU de Liège, University of Liège, Liège, Belgium
González-Martin, A. (författare)
GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain
Ottevanger, P.B. (författare)
DGOG and Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands
Baumann, K. (författare)
AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany
Bjørge, L. (författare)
NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, Norway; Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
Lesoin, A. (författare)
GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France
Burges, A. (författare)
AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany
Rosenberg, Per, 1951- (författare)
Linköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US
Gropp-Meier, M. (författare)
AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany
Harrela, M. (författare)
NSGO and Department of Gynoncology and Gynecology and Obstetrics, Kymenlaakso Central Hospital, Kotka, Finland
Harter, P. (författare)
AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany
Frenel, J.-S. (författare)
GINECO and Centre René Gauducheau, Institut de Cancerologie de lOuest, Saint Herblain, France
Minarik, T. (författare)
NSGO and National Institute of Oncology, Bratislava, Slovakia
Pisano, C. (författare)
MITO and Department of Uro-Gynecologic Oncology, Istituto Nazionale per Io Studio e la Cura dei Tumori ‘Fondazione G. Pascale’ IRCCS, Naples, Italy
Hasenburg, A. (författare)
AGO and Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany
Merger, M. (författare)
Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany
du, Bois A. (författare)
AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany
visa färre...
 (creator_code:org_t)
2019-09-06
2020
Engelska.
Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 146:2, s. 439-448
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • AGO-OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front-line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib demonstrated significantly improved progression-free survival (PFS; primary endpoint) compared with placebo. We report final results, including overall survival (OS). Patients with primary debulked International Federation of Gynaecology and Obstetrics (FIGO) stage IIB–IV newly diagnosed ovarian cancer were randomised 2:1 to receive carboplatin (area under the curve 5 or 6) plus paclitaxel (175 mg/m2) on day 1 every 3 weeks for six cycles combined with either nintedanib 200 mg or placebo twice daily on days 2–21 every 3 weeks for up to 120 weeks. Between December 2009 and July 2011, 1,366 patients were randomised (911 to nintedanib, 455 to placebo). Disease was considered as high risk (FIGO stage III with amp;gt;1 cm residuum, or any stage IV) in 39%. At the final analysis, 605 patients (44%) had died. There was no difference in OS (hazard ratio 0.99, 95% confidence interval [CI] 0.83–1.17, p = 0.86; median 62.0 months with nintedanib vs. 62.8 months with placebo). Subgroup analyses according to stratification factors, clinical characteristics and risk status showed no OS difference between treatments. The previously reported PFS improvement seen with nintedanib did not translate into an OS benefit in the nonhigh-risk subgroup. Updated PFS results were consistent with the primary analysis (hazard ratio 0.86, 95% CI 0.75–0.98; p = 0.029) favouring nintedanib. The safety profile was consistent with previous reports. © 2019 UICC

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

antiangiogenic; nintedanib; ovarian cancer; overall survival; tyrosine kinase inhibitor

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy